key: cord-0279194-4th5ba78
authors: Miesse, P. K.; Collier, B. B.; Grant, R. P.
title: Monitoring of SARS-CoV-2 Antibodies Using Dried Blood Spot for At-Home Collection
date: 2021-11-19
journal: nan
DOI: 10.1101/2021.11.19.21266532
sha: cc9e2fde3696e9e399c51c1024ca7aaed9b8e0a2
doc_id: 279194
cord_uid: 4th5ba78

The utilization of vaccines to fight the spread of SARS-CoV-2 has led to a growing need for expansive serological testing. To address this, an EUA approved immunoassay for detection of antibodies to SARS-CoV-2 in venous serum samples was investigated for use with dried blood spot (DBS) samples. Results from self-collected DBS samples demonstrated a 98.1% categorical agreement to venous serum with a correlation (R) of 0.9600 while professionally collected DBS samples demonstrated a categorical agreement of 100.0% with a correlation of 0.9888 to venous serum. Additional studies were performed to stress different aspects of at-home DBS collection, including shipping stability, effects of interferences, and other sample-specific robustness studies. These studies demonstrated a categorical agreement of at least 95.0% and a mean bias less than {+/-}20.0%. Furthermore, the ability to track antibody levels following vaccination with the BioNTech/Pfizer vaccine was demonstrated with serial self-collected DBS samples from pre-dose (Day 0) out to 19 weeks.

Despite the implementation of several measures to slow the spread of the disease, severe 27 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an international public 28 health emergency due to rapid human-to-human transmission and prevalence of asymptomatic 29 carriers (1,2). Initially, many countries implemented physical distancing protocols and/or 30 lockdown restrictions (3) . In addition, diagnostic tests were quickly developed and granted FDA 31 emergency use authorization (EUA) in order to identify individuals with active SARS-CoV-2 32 infections (4) . Although social distancing and diagnostic testing continue to be vital to ending the 33 pandemic, the advent of SARS-CoV-2 vaccines provides a more robust means of limiting the 34 spread of the virus (4). By triggering the body's natural immune response, vaccines initiate the 35 creation of antibodies that can neutralize the virus upon infection and ultimately reduce the severity 36 of infections as well as transmission of the virus (5) . Unfortunately, the lifespan of circulating 37 SARS-CoV-2 antibodies and the requisite titer to yield protective immunity against SARS-CoV-38 2 is still unclear (5, 6) . These concerns are further confounded by potential immunological 39 differences between immunization versus native infection and the evolutionary nature of the virus 40 (i.e. virus variants) (5) . 41 observed for all levels greater than the DBS LOD. As both imprecision and bias results indicate 149 an LOQ less than the observed LOD, the LOQ for DBS extracts is in practice equivalent to the 150 LOD -0.180 U/mL (16) . 151

Investigation of the DBS assay's LOB, LOD, and LOQ indicates that a lower reporting 152 limit can be achieved for DBS extracts. This may be attributable to the reduction of sample 153 dependent matrix effects as a result of ~10-fold extraction (dilution) with the approved assay 154 diluent (19) . As a result of the increased sensitivity, a clinical cutoff value below the EUA 155 approved assay's LOQ for serum and plasma can be implemented for DBS extracts, enabling 156 assessment of categorical agreement between venous and DBS samples near the serum cutoff (0.8 157 U/mL). 158

Linearity of the assay with DBS samples was assessed using 11 antibody concentrations 160 made through serum sample admixtures in 10% increments followed by contrivance into DBS 161 (Supplementary Section 4). Initial assessment of linearity indicated acceptable biases (±20.0%) 162 from 0.0667 to 147 U/mL with 147 U/mL being the highest concentration tested. This study was 163 repeated with samples of higher concentration to extend the measurement range to 250 U/mL in 164 order to match the reporting limit of un-diluted samples for the EUA approved assay. For this 165 second study, samples with extracted concentrations that initially measured > 250 U/mL were 166 manually diluted 10-fold with Universal Diluent and re-measured as indicated in the assay's 167 package insert (14). Antibody concentrations for this second study ranged from 0.0974 to 323 168 U/mL and targets were determined by using a linear fit of all data points. 169 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

The clinical cutoff, used to assign DBS results as negative or positive for antibodies, for 171 DBS samples was created using results from self-collected samples from donors confirmed to be 172 seronegative (n = 77, Supplementary Section 5). The standard deviation of these results (0.0405 173 U/mL) was multiplied by 3 and added to the mean (0.0625 U/mL) to give a value of 0.184 U/mL. 174

The DBS clinical cutoff for positivity was then set to >0.185 U/mL, where all results less than 175 0.185 are reported as negative. 176

Evaluation of the detection capability of the assay with DBS extracts indicates that sample 178 concentrations can be measured from 0.180 U/mL (LOD/LOQ) to 250 U/mL (upper reporting limit 179 of assay) with a clinical negative/positive antibody cutoff concentration of 0.185 U/mL. This DBS 180 range represents a calculated serum measurement range of 2.6 to 3,570 U/mL. Although dilution 181 of samples is performed for venous serum and plasma samples for the EUA approved in order to 182 extend the reporting limit, dilution of DBS samples is not currently utilized due to the relatively 183 wider concentration range that can be reported for DBS samples (as a result of pre-dilution through 184 extraction). 185

Assay imprecision was assessed for DBS extracts using two reagent lots over a 4-day 187 period with 6 contrived blood samples that covered a range of antibody concentrations (0.504 to 188 156 U/mL). A total of 16 replicates for each sample were measured (Supplementary Section 6). 189

For both reagent lots, the CVs observed for repeatability and within-laboratory imprecision were 190 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use continuous line numbering in your manuscript. less than 15.0% which meets FDA specifications for ligand binding assays (Table 1) Comparison of serum samples with DBS obtained through self-collection demonstrated a 207 high degree of agreement (R = 0.96) and Deming slope of 0.069 (n = 108), which is attributed to 208 dilution of the sample through the extraction process as well as precise but incomplete recovery of 209 antibodies ( Figure 1A and 1C). Two donors with negative venous serum results had self-collected 210 DBS samples that measured positive for antibodies (results within 3.5x the DBS clinical cutoff, 211 Supplementary Section 7). As a result of these two false positives as well as a false negative donor 212 with unmeasurable antibody results for both serum and DBS, qualitative total categorical 213 agreement of self-collected DBS samples compared to venous serum results was 98.1% (Table  214   2A ). In addition, the negative percent agreement (NPA) and positive percent agreement PPA were 215 found to be 97.4% and 100.0%, respectively. When compared to RT-PCR results, qualitative 216 categorical agreement was 97.2% with an NPA and PPA of 97.3% and 97.1%, respectively (Table  217 2B). Results below and above the DBS measurement range were interpreted as negative and 218 positive, respectively. 219

When quantitatively comparing professionally-collected DBS samples to serum results (n 220 = 106), results were similar to self-collected results with a correlation coefficient (R) of 0.9888 221 and a Deming slope of 0.070 ( Figure 1B and 1D) . Total qualitative categorical agreement (n = 222 111) to venous serum results was 100.0% (Table 2C) . When compared to RT-PCR results, 223 qualitative categorical agreement was 99.1% with an NPA and PPA of 100.0% and 97.0%, 224 respectively (Table 2D) . These results met FDA guidance at the time of these studies (NPA ≥ 225 95.0%, PPA ≥ 90.0%) (13). 226

In order to evaluate sample stability during the shipping process, simulated shipping studies 228 were performed in accordance with ISTA 7D guidance as recommended by the FDA (13,21) 

For shipping excursion studies, contrived blood samples were created in triplicate and split 242 into three shipping conditions: baseline ambient (20-25°C), winter and summer excursions 243 (Supplementary Section 8). Results less than 0.180 U/mL (DBS assay LOQ) were included in 244 qualitative analysis but excluded from quantitative analysis. Overall, the sample results from 245 winter and summer excursions both demonstrated total categorical agreement of 97.4% with mean 246 biases of 6.0% and -0.5%, respectively (Table 3 ). These results indicate that samples are stable 247 from the time of collection in an individual's home until received in the laboratory. 248

For robustness studies, results that were found to be less than the assay's DBS LOQ were 250 excluded from bias analysis but included in qualitative analysis. Investigation of drying times 251 compared to the recommended drying time of 3 hours (prior to sample storage) was performed. 252

Samples that were immediately stored after contrived blood was added to the card had a categorical 253 agreement of 95.0% and mean bias of -32.5%. Results from samples that were dried for 1 and 22 254 hours demonstrated categorical agreements of 95.0 and 100.0%, respectively with mean bias of 255 1.3% for both ( Table 3) . Effects of drying samples in a humid environment (40°C, 95% RH) were 256 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint also investigated (23). All results observed had a categorical agreement of 95.0%, but the 257 magnitude of the bias increased from -13.3% for 1 hour to -44.6% for 22 hours of humid drying. 258

Contamination as a result of potential errors in the collection process was investigated 259 ( Although all robustness studies had a total categorical agreement greater than or equal to 95.0%, 264 biases less than ±20.0% were observed in some instances. As these studies are not exhaustive of 265 all possible contaminants, proper instruction materials must be provided to the patient in order to 266 insure the collection of a sample of sufficient quality for measurement. 267

Several studies were performed to assess the effects of different endogenous and 269 exogenous interferents on the measurement of SARS-CoV-2 antibodies from DBS samples 270 (Supplementary Section 10). Results from all interference studies had a categorical agreement 271 greater than or equal to 95.0% to baseline measurements ( Table 4) . The exogenous interferents 272 tested had mean biases less than ±5.0% while most endogenous interferents tested had a mean bias 273 result less than ±10.0% with the exception of excess protein (17.7%). 274

Application of self-collected DBS was performed with serial monitoring of SARS-CoV-2 276 antibody levels following immunization in 8 donors. Donors periodically performed self-277 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint collection of DBS samples pre-vaccination through 19 weeks following initial vaccination. All 278 donors reported receiving the Pfizer-BioNTech COVID-19 vaccine with the second dose occurring 279 exactly 3 weeks following the first dose. As can be seen in Figure 2A below, all donors had 280 negative DBS results for samples collected within the first 9 days following initial immunization. 281

Antibody levels for each donor rose above the DBS cutoff of 0.185 U/mL between days 10 and 282 16. Antibody levels increased rapidly following the second vaccination dose ( Figure 2B ), with 283 several donors reaching levels greater than the DBS reporting limit (250 U/mL which is calculated 284 to be 3570 U/mL in serum) (22,23). Dramatically lower antibody levels were observed for Donor 285 7, likely a result of the immunosuppressive medication the donor reported taking for a chronic 286 condition (24). 287

The thorough results provided herein demonstrate the robustness of measuring SARS-289

CoV-2 antibodies using DBS samples. Although DBS samples are diluted through the extraction 290 process (and as a result of incomplete antibody recovery), this approach also has advantages. 291

Using Roche's Universal Diluent as the extraction buffer, sample-to-sample matrix effects were 292 reduced and a lower (absolute) reporting limit was achieved (LOQ of 0.180 U/mL for DBS 293 samples). In addition, the dilution of the sample allowed a higher relative measurement range to 294 be demonstrated as a DBS samples with a concentration of 250 U/mL DBS sample (upper limit of 295 quantitation for un-diluted venous samples) would be greater than 3,500 U/mL in serum. These 296 results, as well as the high correlation to venous serum results, allowed the assay to be used to 297 demonstrate antibody monitoring over time through at-home DBS self-collections. Ultimately, 298 DBS samples could serve as an important tool for regular antibody monitoring and scheduling of 299 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Six pre-pandemic serum samples were utilized to assess the assay's limit of blank (LOB) following creation into contrived blood samples for spotting and extraction from DBS cards. This produced 16 total measurements for each sample for a total of 96 "blank" measurements for each lot. A single instrument was used for this study. In accordance with CLSI EP17-A2 guidance, the mean ( ) and standard deviation ( ) of all samples was determined across two reagent lots (1). All results from sample 4 on Day 2, Run 1 were excluded as the z-score of these results was greater than 4.7 with respect to other results measured using the same lot. In addition to the mean and standard deviation, a multiplier ( ) which represents the 95 th percentile of normal distribution was utilized. This multiplier was corrected for the use of the biased observed standard deviation estimate using equation 1 below where B represents the total number of blank results in the dataset (B = 94) and K represents the number of blank samples (K = 6). The mean and standard deviation observed for reagent lot 53688601 were 0.0617 and 0.0296 U/mL, respectively (Table 1) . With a multiplier value of 1.6497, the calculated LOB for reagent lot 53688601 was 0.111 U/mL. For reagent lot 54862501, the mean and standard deviation was determined to be 0.0417 and 0.0298 U/mL, respectively, giving a LOB of 0.0908 U/mL ( Table 2) .

As the calculated LOB for reagent lot 53688601 is greater, it represents the LOB listed in the manuscript.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Five (5) contrived DBS samples were created to have concentrations that were expected to cover the clinical cutoff range (0.126 to 0.415 U/mL), which allows assessment of the assay's LOB. DBS extracted and measured in duplicate for each run with 2 runs being performed per day over 4 days giving 16 total measurements for each sample. A single instrument was used for this study. In accordance with CLSI EP05-A3 and EP17-A2 guidance, the within laboratory standard deviation of all samples was determined across two reagent lots (1). The pooled standard deviation ( ) was then determined using (2):

where represents the SD of all results for the ith low level sample, is the number of results for the ith low level sample ( = 16), and is the number of low level samples ( = 5). Using equation 3, the pooled standard deviation for reagent lot 53688601 was found to be 0.0419 U/mL (Table 3 ) and 0.0346 U/mL for reagent lot 54862501 ( Table 4 ). The larger of these values, 0.0419 U/mL was used with LOB results and a multiplier to determine the assay's LOD:

where is the total number of all low level sample ( = 80). The LOD was calculated with a multiplier of 1.6505, and the reported LOB (0.111 U/mL) to give a LOD of 0.180 U/mL.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; confidence interval of this fit is equal to the target CV. For this application, the target CV was set to 25% based on the FDA guidance for ligand binding assays at the lower limit of quantitation (3).

Based on imprecision results, reagent lot 51595100 had a LOQ of 0.0873 U/mL while reagent lot 53688600 had a LOQ value of 0.0736 U/mL (Figures 1 and 2) . Both of these results are less than the assay's LOD.

In addition, LOQ results were evaluated in terms of bias where acceptable biases were also set to 25% based on FDA guidance. Bias results (Tables 5 and 6 ) indicated acceptable bias for all levels greater than the assay's LOD. As both imprecision and bias results indicated an LOQ less than the assay's LOD, the reported LOQ for the assay is in practice equivalent to the LOD (0.180 U/mL).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint 

Linearity was performed using positive and negative serum pools that were admixed in 10%

increments to create 11 different serum concentrations of SARS-CoV-2 antibodies. Contrived blood samples were created using these different admixtures and applied to DBS cards. Following extraction and measurement, the initial linearity results indicated a linearity from 0.0677 to 147 U/mL for DBS samples (Table 7) . Additional linearity results indicated acceptable biases (≤ 20.0%) for all concentrations measured between 0.0974 and 323 U/mL for DBS samples (Table   8 ). DBS samples that initially measured greater than 250 U/mL were manually diluted 10-fold with Universal Diluent and re-measured.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint *Extracts were manually diluted 10-fold and re-measured. Results were multiplied by 10.

Inter-assay imprecision was performed over 4 different days with two replicates being measured per run and two runs occurring per day for a total of 16 replicates from 6 different contrived blood samples. A single instrument was used for this study. DBS samples spanned an antibody concentration range of 0.517 (~3 times DBS cutoff) to 177 U/mL (~1000 times DBS cutoff) using two different reagent lots (53688601 and 54682501). Repeatability, withinlaboratory imprecision, and total variance (% CV) was less than 20.0% (Table 9 and Table 10 ) for both reagent lots and is considered acceptable relative to FDA guidance for ligand binding assays (3) . All the samples had total categorical agreement of 100.0%.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Nnegative, Ppositive, Aresults agree, Dresults disagree Nnegative, Ppositive, Aresults agree, Dresults disagree

In order to report DBS samples categorically negative or positive, a clinical cutoff value was determined. This was calculated using the self-collected DBS samples from donors that were confirmed to be seronegative and did not have an active COVID-19 infection (Donors with "B" pre-fix in Table 11 ). The mean and standard deviation for results from self-collected DBS samples were found to be 0.0625 and 0.0405 U/mL, respectively (n = 78). The cutoff was set by multiplying the standard deviation by three and adding the mean to give a value of 0.184 U/mL. As such, the clinical cutoff was set to 0.185 U/mL where all results greater than or equal to this value were considered positive (P) and all values less than 0.185 considered negative (N).

For the clinical performance studies, some results were not obtained for all sample types from all donors (Table 11 ). Either a sample was not provided for testing or the sample did not have sufficient volume for measurement (e.g. insufficient volume on DBS card for extraction and measurement, QNS). Serum samples that initially measured greater than 250 U/mL were manually diluted 10-fold with the approved Roche Universal Diluent and re-measured; results were multiplied by 10. In addition, some samples had results that were reported by the instrument as "< Test" indicating the signal generated was less than the intercept of the calibration curve used to calculate a concentration. Donors with a pre-fix of "A" previously tested positive for COVID-19

using an RT-PCR test while donors with a pre-fix of "B" are presumed negative.

All serum and DBS results where a definitive number was not obtained were excluded from quantitative analysis. Six donors (B10, B35, B51, B64, B-077, B80) that were reported to have never had COVID-19 as well as confirmed not to have an active SARS-CoV-2 infection had venous serum, professionally collected DBS, and self-collected DBS samples results all measure . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint as positive. To confirm these results, serum was measured using three additional EUA approved antibody assay: Roche Elecsys ® Anti-SARS-CoV-2 (qualitative nucleocapsid assay), DiaSorin Liason SARS-CoV-2 S1/S2 IgG (qualitative spike protein assay) and DiaSorin Laison SARS-CoV-2 IgM (qualitative spike protein assay) (4). All six donors had a positive serum test result for at least one additional assay (Table 12 ). As such, these donors were excluded from qualitative and quantitative method comparison data analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 19, 2021. ; 

Studies were performed to evaluate sample stability during the shipping process including storage of samples before shipping, samples sitting prior to pick up, and conditions following pick up and transport to the lab for testing (5, 6) . Contrived blood samples (n = 76) were prepared with antibody concentrations ranging from 0.0358 U/mL (~0.2 times DBS cutoff) to 4.91 U/mL (~27 times DBS cutoff); most samples (n = 70) were within 5 times the DBS cutoff. Samples were made into triplicates and were divided into three shipping conditions: ambient (20-25°C), winter, and summer (refer to Table 13 ). Samples were measured in parallel whereas the room temperature samples were used as baseline results. Results that were less than the assay's DBS LOQ were excluded from bias analysis but included in qualitative analysis. Winter and summer excursion samples had a total categorical agreement of 97.4% and mean biases of 6.0% and -0.5%, respectively. One winter excursion sample that did not have categorical agreement had a baseline . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 19, 2021. ; Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Additional robustness studies were performed to stress different aspects of sample collection. Contrived blood samples were prepared with antibody concentrations ranging from 0.0380 U/mL (~0.2 times DBS cutoff) to 1.52 U/mL (~8 times DBS cutoff); most samples were within 5 times the DBS cutoff. All samples used to generate baseline results were spotted and dried for three hours prior to storage; no interferents or contamination was introduced. For acceptance of results, biases were determined to baseline measurements for results greater than the assay's LOQ. A mean bias of 20% was used as quantitative acceptance following FDA guidance for ligand binding assays (3). For qualitative assessment, a total categorical agreement of 95.0% was utilized based on guidance from the FDA's Home Specimen Collection Serology Template . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

To test the effects of drying time on sample results, alternative drying times were investigated using antibody concentrations designed to stress the clinical cutoff. Drying times prior to storage were 0, 1, 3 (baseline), and 22 hours (overnight). Following the pre-determined drying time, samples were placed in plastic specimen pouches (without desiccant) and stored at room temperature until measurement. DBS samples that were immediately stored after being spotted demonstrated total categorical agreement of 95.0% and mean bias of -32.5% and total categorical agreement of 95.0% versus DBS samples stored for 3 hours prior to placing in a desiccant free specimen pouch. The one sample that did not have categorical agreement with baseline results had a baseline concentration of 0.193 U/mL which is within 5% of the DBS clinical cutoff (0.185 U/mL). DBS samples that dried for one hour demonstrated total categorical agreement of 95.0% and mean bias of 1.3%. The one sample that did not have categorical agreement with baseline results had a baseline concentration of 0.176 U/mL which is again within 5% of the DBS clinical cutoff (0.185 U/mL). DBS samples stored for 22 hours demonstrated total categorical agreement of 100% and mean bias of 1.3% (Table 15 ). These results indicate that at least 1 hour of drying is required prior to sample storage and shipment. Risk of donors not allowing sufficient drying can be mitigated by appropriate design of donor materials including instructions for use (IFUs) and demonstration videos.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; Nnegative, Ppositive, Aresults agree, Dresults disagree

Studies were performed to evaluate the effects of DBS samples drying under humid conditions.

Four sample replicates were created for each concentration, where 3 of the 4 DBS samples were placed into an incubator at 40°C with a water pan in the bottom to simulate a relative humidity greater than 95%. The 4th sample replicate (baseline) was stored at room temperature and placed in a plastic specimen pouch after 3 hours of drying.

All samples that remained in a humid environment demonstrated total categorical agreement of 95.0%, with increasing mean biases of -13.3% (1 hour), -22.2% (3 hours) and -44.6% (22 hours, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint Nnegative, Ppositive, Aresults agree, Dresults disagree

The potential effects of alcohol exposure to DBS cards prior to addition of blood was investigated in the event that an individual did not allow their finger to dry after sterilization with an alcohol wipe. This study was performed by wiping an alcohol pad on a DBS card immediately prior to the addition of contrived blood samples to the card. For this study all samples were stored after three hours of drying and stored at room temperature. All samples demonstrated total categorical agreement of 100%, with a mean bias of -11.0% ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ;

The effects of an unsterilized finger being exposed to a DBS spot was investigated by pressing an ungloved finger directly on a DBS card immediately prior to the addition of contrived blood samples. For this study all samples were stored after three hours of drying and stored at room temperature. Total qualitative categorical agreement of 95.0% was observed with mean bias of 1.3% (Table 18 ). As this study represents a worst case scenario to finger exposure, these results are considered acceptable. The one sample that did not have categorical agreement with baseline results had a baseline concentration of 0.208 U/mL which is within 13% of the DBS clinical cutoff (0.185 U/mL). Risk of donors contaminating DBS cards prior to addition of blood can be mitigated by appropriate design of donor materials including instructions for use (IFUs) and demonstration videos.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Studies were also performed to test the effects of different interferences on the measurement of SARS-CoV-2 antibodies from DBS samples. Contrived blood samples were prepared with antibody concentrations ranging from 0.0342 U/mL (~0.2 times DBS cutoff) to 1.52 U/mL (~175 times DBS cutoff); most samples were within 5 times the DBS cutoff. All samples used to generate baseline results were spotted and dried for three hours prior to being stored. For acceptance of results, biases were determined to baseline measurements for results greater than the assay's LOD.

A mean bias of 20.0% was used as quantitative acceptance following FDA guidance for ligand binding assays (3) . For acceptance of qualitative results, a total categorical agreement of 95.0% was utilized based on guidance from the FDA's Home Specimen Collection Serology Template (5).

To test the effects of hemolysis, contrived liquid blood samples were prepared in duplicate aliquots. One of the aliquots was frozen at -70°C for at least 30 minutes and thawed in order to lyse the red blood cells. Both aliquots (lysed and un-lysed) were then spotted onto DBS cards, dried and stored prior to testing. A total qualitative categorical agreement of 95.0% to un-lysed measurements was observed, one sample disagreed (D) with baseline results with a measured concentration of 0.208 U/mL, within 13% of the DBS clinical cutoff (0.185 U/mL). Lysed DBS samples demonstrated an acceptable mean bias of 3.6% compared to baseline measurements (Table 19) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Endogenous interferents were spiked directly into serum samples prior to adding red blood cells to make contrived blood samples, then spotted onto DBS cards (Table 20) . To account for dilution of the serum with the interferent a paired (un-spiked) serum was diluted with a confirmed negative serum (blank) using the same dilution ratio. The spiked and un-spiked serum were then made into contrived blood samples and spotted onto DBS cards. All samples followed the recommended drying and overnight storage, samples were extracted the following day and results were compared to paired samples without interferents. For acceptance criteria of results, the FDA guidelines were used for quantitative and qualitative analysis (3, 5) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

When spiking samples with triglycerides at a concentration of 3000 mg/dL, DBS results were found to have a categorical agreement of 96.7%. The one sample that did not have categorical agreement had a baseline concentration of 0.179 U/mL which is within 4.0% of the DBS clinical cutoff (0.185 U/mL). Overall, the triglyceride spiked DBS samples had a mean bias of 4.5% compared to baseline results (Table 21) . These results were acceptable under the FDA guidelines for the mean bias and categorical agreement (3, 5) . 

Following spiking of DBS samples to create additive protein concentrations of 12 g/dL, measurements indicated a total qualitative categorical agreement of 100% and mean bias of 17.7% when compared to baseline measurements (Table 22) . These results were acceptable under the FDA criteria for the mean bias and categorical agreement (3, 5) . Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ;

Spiking of conjugated bilirubin (up to 20 mg/dL) into DBS samples demonstrated a categorical agreement of 96.7% with baseline DBS samples with a mean bias of -2.8% (Table 23 ). The one sample that did not have categorical agreement had a baseline concentration of 0.0653 U/mL and a spiked concentration of 0.215 U/mL which is within 16.0% of the DBS clinical cutoff (0.185 U/mL). Spiking of DBS samples with unconjugated bilirubin demonstrated a categorical agreement of 100.0% with baseline results with a mean bias of -8.7% (Table 23 ). These results were acceptable under the FDA guidance for mean bias and categorical agreement (3, 5) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; (Table   24 ). The one sample that did not agree with baseline measurements had a measured baseline concentration (0.205 U/mL) within 11% of the DBS clinical cutoff (0.185 U/mL). These results indicate that DBS measurements in the presence of biotin levels up to 3,510 ng/mL are acceptable under the FDA guidance for the mean bias and categorical agreement (3, 5) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Serum samples were spiked with pharmaceutical interferents (from Cerilliant Analytical Reference Standards) and then red blood cells were added to make contrived blood samples that were spotted on DBS cards (Table 25) . To account for dilution of the serum with the interferent a paired (un-spiked) serum was diluted with a confirmed negative serum (blank) using the same dilution ratio. The spiked and un-spiked serum were then made into contrived blood samples and spotted onto DBS cards. Samples dried for the recommended time of three hours prior to storage. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint DBS samples spiked with Cerilliant mix 1 had a total categorical agreement of 96.6% with baseline DBS results (Table 26) . One of the thirty Cerilliant mix 1 DBS samples was in disagreement with baseline; DBS results were less than 1% greater than the DBS clinical cutoff (0.186 versus the cutoff of 0.185 U/mL). Mean bias was 5.8% when compared to baseline results.

Samples that were spiked with Cerilliant mix 2 had a total categorical agreement of 100.0% with baseline DBS results. Overall, Cerilliant mix 2DBS results had a mean bias -0.2% when compared to baseline DBS results (Table 27 ). These results indicate that DBS samples containing supraphysiological levels of tested drugs from Cerilliant mix 1 and 2 are acceptable under the FDA guidance for the mean bias and categorical agreement (3, 5) . Cerilliant mix 1 and 2 DBS results were within the acceptance criteria provided by the FDA.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint Nnegative, Ppositive, Aresults agree, Dresults disagree . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266532 doi: medRxiv preprint

Factors associated with the 318 11. References 1. Clinical and Laboratory Standards Institute. EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline. Second. 2012. 2. Clinical and Laboratory Standards Institute. EP05-A3 Evaluation of precision of quantitative measurement procedures

Department of Health and Human Services, Food and Drug Administration

Bioanalytical Method Validation: Guidance for Industry

Food & Drug Administration. EUA Authorized Serology Test Performance

Food & Drug Administration. Home Specimen Collection Serology Template for Fingerstick Dried Blood Spot (DBS) | FDA

International Safe Transit Association. Temperature Test for Transport Packaging

Series Developemt Test Procedure